Vanguard Capital Management
EBS icon

Vanguard Capital Management’s Emergent Biosolutions EBS Stock Holding History

Vanguard Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Sell
2,198,839
-59,156
-3% -$495K ﹤0.01% 2487
2026
Q1 		$18.7M Buy
+2,257,995
New +$23.4M ﹤0.01% 2380

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management's EBS Position: Q2 2026 in Review

Vanguard Capital Management reduced its Emergent Biosolutions (EBS) stake by 2.6% in Q2 2026, selling an estimated $495K and leaving 2,198,839 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Vanguard Capital Management first reported a position in EBS in Q1 2026 and has held it in 2 quarters since. The position peaked at $18.7M in Q1 2026. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Vanguard Capital Management held 2,198,839 shares of Emergent Biosolutions worth $18.4M as of Q2 2026.
  • Vanguard Capital Management sold 59,156 Emergent Biosolutions shares in Q2 2026, an estimated $495K.
  • Emergent Biosolutions made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2487 holding.
  • Vanguard Capital Management first reported a position in Emergent Biosolutions in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Emergent Biosolutions position peaked at $18.7M in Q1 2026.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.